Bone marrow mesenchymal stem cells-derived exosomal microRNA-19b-1-5p reduces proliferation and raises apoptosis of bladder cancer cells via targeting ABL2

Fu, Dewang; Liu, Ben; Jiang, Huamao; Li, Zhaowei; Fan, Chenghui; Zang, Li'e

doi:10.1016/j.ygeno.2021.03.011

Cited by 12 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By analysing BC tissues and paired normal tissues from 30 patients, it was confirmed that the mRNA expression of CYP1B1, ABL2 and MAP1B in BC tissues was significantly greater than that in normal tissues (Figure 7G-I). Among the three hub genes, two genes (MAP1B and ABL2) have been reported to have an impact on the malignant traits of BC cells 26,27 ; therefore, we selected CYP1B1 as the target for subsequent experimental verification. CYP1B1 mRNA was significantly reduced in BC cells after transfection (Figure 7J,K).…”

Section: Knockdown Of Cyp1b1 Inhibited the Proliferation And Migratio...mentioning

confidence: 99%

Construction of endothelial cell signatures for predicting the diagnosis, prognosis and immunotherapy response of bladder cancer via machine learning

Fu,

Sun,

Shi

et al. 2024

J Cellular Molecular Medi

View full text Add to dashboard Cite

We subtyped bladder cancer (BC) patients based on the expression patterns of endothelial cell (EC) ‐related genes and constructed a diagnostic signature and an endothelial cell prognostic index (ECPI), which are useful for diagnosing BC patients, predicting the prognosis of BC and evaluating drug sensitivity. Differentially expressed genes in ECs were obtained from the Tumour Immune Single‐Cell Hub database. Subsequently, a diagnostic signature, a tumour subtyping system and an ECPI were constructed using data from The Cancer Genome Atlas and Gene Expression Omnibus. Associations between the ECPI and the tumour microenvironment, drug sensitivity and biofunctions were assessed. The hub genes in the ECPI were identified as drug candidates by molecular docking. Subtype identification indicated that high EC levels were associated with a worse prognosis and immunosuppressive effect. The diagnostic signature and ECPI were used to effectively diagnose BC and accurately assess the prognosis of BC and drug sensitivity among patients. Three hub genes in the ECPI were extracted, and the three genes had the closest affinity for doxorubicin and curcumin. There was a close relationship between EC and BC. EC‐related genes can help clinicians diagnose BC, predict the prognosis of BC and select effective drugs.

show abstract

Section: Knockdown Of Cyp1b1 Inhibited the Proliferation And Migratio...mentioning

confidence: 99%

Construction of endothelial cell signatures for predicting the diagnosis, prognosis and immunotherapy response of bladder cancer via machine learning

Fu,

Sun,

Shi

et al. 2024

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…ABL2 is up-regulated while miR-19b-1-5p is down-regulated in bladder cancer tissues and cell lines, according to another research. Recently, the research revealed that BMSCs-derived exosomal miR-19b-1-5p could inhibit bladder cancer cell lines (T24, UC3, 5637, and J82) from migrating, proliferating, or invading while promoting cell death via inhibiting ABL2, Bcl-2, MMP2 and MMP9 ( Fu et al, 2021 ).…”

Section: Urologic Neoplasms and Mscs Derived Exosomesmentioning

confidence: 99%

Mesenchymal stromal/stem cell-derived exosomes and genitourinary cancers: A mini review

Salehpour¹,

Balmagambetova

Mussin

et al. 2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Mesenchymal stromal/stem cell- (MSC-) derived exosomes are gaining popularity for their involvement in tissue repair and repressing various tumors through extensive patterns. Nevertheless, the impact of extracellular vesicles produced by stem cells on tumor formation and progression is controversial and seems to depend on several factors. The utilization of MSCs’ various capabilities in urogenital neoplasms is widely regarded as a potential future therapeutic as well. These genitourinary neoplasms include prostatic neoplasms, ovarian neoplasms, cervical neoplasms, endometrial neoplasms, bladder neoplasms, and renal cell neoplasms. The present study has concentrated on the most recent information on genitourinary neoplasms employing MSCs derived exosomes’ many capabilities, such as delivering effective RNAs, extensive tissue compatibility, and specificity with tumor identification without inherent limitations of cell therapy.

show abstract

“…It has also been indicated that BM‐MSC‐derived exosomal miR‐19b‐1‐5p decreased ABL2, leading to suppression of invasion, proliferation, and migration, and the promotion of apoptosis in BCa cells. Nevertheless, due to the limited existing research, the precise mechanism behind exosomal miR‐19b‐1‐5p and ABL2 remains unclear, necessitating further large‐scale studies to clarify the underlying mechanism (Fu et al, 2021). It was observed that the exosomal lncRNA PTENP1 inhibited bladder tumor growth in nude mice by regulating the miR‐17/SCARA5 axis.…”

Section: The Beneficial Characteristics Of Mscsmentioning

confidence: 99%

Mesenchymal stem cells and their extracellular vesicles in urological cancers: Prostate, bladder, and kidney

Saadh,

Alhuthali,

Gonzales Aníbal

et al. 2023

Cell Biology International

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are recognized for their remarkable ability to differentiate into multiple cell types. They are also known to possess properties that can fight cancer, leading to attempts to modify MSCs for use in anticancer treatments. However, MSCs have also been found to participate in pathways that promote tumor growth. Many studies have been conducted to explore the potential of MSCs for clinical applications, but the results have been inconclusive, possibly due to the diverse nature of MSC populations. Furthermore, the conflicting roles of MSCs in inhibiting tumors and promoting tumor growth hinder their adaptation to anticancer therapies. Antitumorigenic and protumorigenic properties of MSCs in urological cancers such as bladder, prostate, and renal are not as well established, and data comparing them are still limited. MSCs hold significant promise as a vehicle for delivering anticancer agents and suicide genes to tumors. Presently, numerous studies have concentrated on the products derived from MSCs, such as extracellular vesicles (EVs), as a form of cell‐free therapy. This work aimed to review and discuss the current knowledge of MSCs and their EVs in urological cancer therapy.

show abstract

Bone marrow mesenchymal stem cells-derived exosomal microRNA-19b-1-5p reduces proliferation and raises apoptosis of bladder cancer cells via targeting ABL2

Cited by 12 publications

References 30 publications

Construction of endothelial cell signatures for predicting the diagnosis, prognosis and immunotherapy response of bladder cancer via machine learning

Construction of endothelial cell signatures for predicting the diagnosis, prognosis and immunotherapy response of bladder cancer via machine learning

Mesenchymal stromal/stem cell-derived exosomes and genitourinary cancers: A mini review

Mesenchymal stem cells and their extracellular vesicles in urological cancers: Prostate, bladder, and kidney

Contact Info

Product

Resources

About